Filing Flows › RenovoRx (RNXT) › Q4 2025
RenovoRx (RNXT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
RenovoRx (RNXT) reported revenue of $238K for the fourth quarter 2025 (Q4 2025) and -11% from the quarter before.
RenovoRx, Q4 2025: revenue $238K, net loss $2.9M, operating cash flow −$3.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $238K | -11% | — |
| Operating profit | −$3.5M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$3.0M | — | — |
What changed
Revenue was $238K in Q4 2025, down 11% from the previous quarter.
Gross margin was 88.2%. Operating costs exceeded revenue by $3.5M, an operating margin of -1479.8%. The quarter ended with a net loss of $2.9M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$3.0M. Non-cash charges added back $285K of share-based compensation. Working capital and other items used $364K.
Questions
What was RenovoRx's revenue in the fourth quarter 2025?
RenovoRx (RNXT) reported revenue of $238K for the fourth quarter 2025 (Q4 2025) and -11% from the quarter before.
Source: RenovoRx 10-K on SEC EDGAR.